BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180522
DTEND;VALUE=DATE:20180624
DTSTAMP:20260730T163537
CREATED:20180522T111743Z
LAST-MODIFIED:20180522T112043Z
UID:20211-1526947200-1529798399@ces.b2sg.org
SUMMARY:ASSOCIATE SCIENTIST - CANCER IMMUNOLOGY
DESCRIPTION:Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. Neon utilizes its expertise in bioinformatics\, neoepitope prediction and immune monitoring to identify tumor specific mutations and monitor clinical response to their personalized vaccines. Neon Therapeutics’ lead program is NEO-PV-01\, a bespoke neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute. NEO-PV-01 is now being studied in a Phase 1b clinical trial combining the vaccine with Opdivo®\, a PD-1 immune checkpoint inhibitor from Bristol-Myers Squibb\, in patients with measurable metastatic melanoma\, non-small cell lung cancer and bladder cancer. Three additional clinical trials are planned for 2018. Also in development are NEO-PTC-01\, a bespoke autologous T cell therapy\, and NEON / SELECT\, a Shared Neoantigen Program leveraging neoepitopes that are common across patients and tumor types.\nIn addition\, Neon has established strategic partners in BMS\, Merck\, and Apexigen to harness opportunities for combination therapies. Neon leverages foundational intellectual property from the Broad Institute and the Dana-Farber Cancer Institute.Neon Therapeutics was incubated and launched by Third Rock Ventures and raised a $55M Series A in 2015 and\, more recently\, a $106M Series B in 2017. \n\nPosition Summary \nThe successful candidate will work in the Neon SELECT program that aims to develop therapies against neoantigen targets shared across patients. S/he will focus on generating and studying T cell responses to shared neoantigens\, with particular focus on peptide design and T cell receptor characterization. The candidate will need to work on a team but also independently test many different technologies. S/he will need to work effectively on a team while also independently perform cell and molecular biology assays. The candidate will work closely with the departments of T cell immunology\, molecular immunology\, peptide chemistry\, and bioinformatics. \nJob Responsibilities: \n\nCulture and manipulation of human T cells\nAssessment and analysis of specificity of human T cells by multicolor flow cytometry\nPerform scRNA and TCR sequencing as well as data analysis\nDesign and analysis of immunogenic peptide sequences\nProduction of stable cell lines using transfection or transduction\nAnalysis and presentation of results to larger scientific groups\nAssist with the training of lab personnel\nWork productively in a team environment and independently and deliver against timelines.\n\nExperience and essential skills: \n\nM.S. with 5-8 years of experience\, or Ph.D. with 0-2 years of experience in industry with a strong background in immunology.\nA strong background in adaptive immunity in the context of cancer is preferred\nDemonstrated mastery of flow cytometry and related data analysis\nExperience with functional immune assays\, such as cytokine analysis\nGeneral molecular biology techniques\, including plasmid cloning and preparation\nExperience with lentivirus preparation and infection\nAbility to organize and tabulate data.\nStrong evidence of leadership background and experience working in cross-functional teams\nExcellent and record-keeping skills.\nStrong written and oral communication skills.\nIndependent\, flexible\, self-motivated.\n\n\nTo apply\, please send your resume to careers@neontherapeutics.com
URL:https://ces.b2sg.org/event/neon-22may18/
LOCATION:Neon Therapeutics\, 40 Erie St\, Cambridge\, MA\, 02139\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/Neon-logo-e1526988012112.jpg
END:VEVENT
END:VCALENDAR